Brisbane-based cancer care provider Icon Group has partnered with Siemens Healthineers’ Varian, a developer of cancer care technology, to reach a research and professional services agreement lasts 5 years.
According to a media release, the partnership will conduct technical and clinical research to evaluate the hardware and software systems involved in diagnosis, treatment planning, and radiation therapy for patients. cancer patient.
WHY IT IMPORTANT
Their first project will focus on using AI in contouring — or outlining tumors and nearby organs — to cut radiation treatment planning time.
“Timely care is critical to improving patient outcomes, and this partnership with Icon builds on our efforts to reduce the time between cancer diagnosis and treatment,” said Kevin O. ‘ said Reilly, Varian president of Radiation Oncology Solutions.
The results of their research projects will later be published and used to support educational efforts in the industry, including radiology system training for healthcare providers. .
“Together with Icon, we can evaluate how new products can integrate into existing systems and continuously improve our technology offerings, all with a focus on enhancing the user experience. patient experience,” says O’Reilly.
Varian and Icon first collaborated last April when Varian installed linear accelerators on Icon’s network in Australia and Asia.
“Through this five-year partnership, we look forward to once again supporting Varian’s world-class team in developing products and services that have the potential to deliver effective care. more advanced for more patients in more regions of the world,” said Icon CEO Mark Middleton.
TREND TO BIGGER
Other healthcare providers have begun their respective research collaborations to investigate how AI can enhance radiology and imaging for cancer.
Medical imaging provider based in New South Wales General X-ray also signed a multi-year agreement to explore the use of AI in clinical radiology. The company will integrate its existing radiology workflows with AI solutions from the Sydney Center for Neuroimaging, a developer of software solutions that automate image analysis for diagnostics. and research.
Egyptian non-profit group Baheya Foundation has also partnered with GE Healthcare to validate the use of AI in the assessment and prediction of neoplastic adjuvant therapy responses in cases of advanced breast cancer.
